|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.50 USD | +0.52% |
|
-4.42% | +1.04% |
| 01-20 | Bristol-Myers Squibb Extends Research Collaboration With Syngene International | MT |
| 01-20 | Bristol-Myers Squibb Collaborates With Microsoft on AI-Driven Early Lung Cancer Detection | MT |
Business description: Bristol-Myers Squibb Company
The United States account for 7.1% of net sales.
Number of employees: 34,100
Sales by Activity: Bristol-Myers Squibb Company
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 42.52B | 46.38B | 46.16B | 45.01B | 48.3B |
Geographical breakdown of sales: Bristol-Myers Squibb Company
| Fiscal Period: December | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) |
|---|---|---|---|---|---|
United States | 26.58B | 29.21B | 31.83B | 31.56B | 34.1B |
International | - | - | 13.5B | 12.75B | 13.2B |
Unallocated | 631M | 852M | 834M | 699M | 996M |
Europe | 9.85B | 10.69B | - | - | - |
Rest of The World | 5.46B | 5.63B | - | - | - |
Executive Committee: Bristol-Myers Squibb Company
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 31/10/2023 | |
David Elkins
DFI | Director of Finance/CFO | 58 | 19/11/2019 |
| Compliance Officer | - | 30/09/2023 | |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Chief Tech/Sci/R&D Officer | - | - |
Composition of the Board of Directors: Bristol-Myers Squibb Company
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 55 | 31/03/2024 | |
Peter Arduini
BRD | Director/Board Member | 61 | 31/03/2016 |
Theodore Samuels
BRD | Director/Board Member | 71 | 20/02/2017 |
Karen Vousden
BRD | Director/Board Member | 68 | 31/12/2017 |
Julia Haller
BRD | Director/Board Member | 71 | 19/11/2019 |
Phyllis Yale
BRD | Director/Board Member | 68 | 19/11/2019 |
Paula Price
BRD | Director/Board Member | 64 | 31/08/2020 |
Derica Rice
BRD | Director/Board Member | 61 | 31/08/2020 |
Manuel Medina
BRD | Director/Board Member | 58 | 31/05/2021 |
Deepak Bhatt
BRD | Director/Board Member | 58 | 13/06/2022 |
Holdings: Bristol-Myers Squibb Company
| Name | Equities | % | Valuation |
|---|---|---|---|
| 5,075,304 | 3.53% | 366 M $ | |
UNIQURE N.V. 3.83% | 2,388,108 | 3.83% | 57 M $ |
PRIME MEDICINE, INC. 6.38% | 11,006,163 | 6.38% | 38 M $ |
| 70,231,140 | 16.86% | 23 M $ | |
COMPUGEN LTD. 1.97% | 1,840,136 | 1.97% | 3 M $ |
COMPUGEN LTD. 1.59% | 177,761 | 1.59% | 1 M $ |
COMPUGEN LTD. 1.63% | 200,244 | 1.63% | 664 810 $ |
CELULARITY INC. 1.78% | 426,372 | 1.78% | 473 273 $ |
Company details: Bristol-Myers Squibb Company
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.com
Group companies: Bristol-Myers Squibb Company
| Name | Category and Sector |
|---|---|
Bristol-Myers Squibb India Pvt Ltd.
 Bristol-Myers Squibb India Pvt Ltd. Discovers, develops and delivers medicines for immuno--oncology | |
Bristol-Myers Squibb India Pvt Ltd.
Bristol-Myers Squibb India Pvt Ltd. Discovers, develops and delivers medicines for immuno--oncology | |
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH | |
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH | |
Bristol-Myers Squibb SA (Switzerland) |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.52% | -4.42% | -4.45% | -26.50% | 110B | |
| +3.58% | +0.49% | +45.28% | +211.65% | 932B | |
| -0.09% | -0.25% | +47.15% | +29.20% | 526B | |
| +0.99% | -2.59% | +25.22% | +44.49% | 378B | |
| -0.38% | +1.11% | +29.15% | +17.13% | 374B | |
| -1.35% | -4.78% | +23.57% | +19.09% | 282B | |
| +0.07% | +0.62% | +28.14% | +35.35% | 278B | |
| -4.02% | -2.47% | -32.19% | -22.60% | 272B | |
| +1.52% | +0.09% | +15.45% | +1.06% | 272B | |
| +3.81% | +4.45% | +25.03% | +30.53% | 178B | |
| Average | -0.00% | -0.56% | +20.24% | +33.94% | 360.22B | |
| Weighted average by Cap. | -0.32% | -0.32% | +28.13% | +68.79% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMY Stock
- Company Bristol-Myers Squibb Company
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition